The American Journal of Managed Care1d
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...
pharmaphorum6d
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
As with Aduhelm (aducanumab), lecanemab is being filed via the accelerated approval pathway, with the companies seeking a green light on the strength of the results of a phase 2b trial ahead of ...
pharmaphorum8d
Biogen, Eisai double down on Alzheimer's with lecanemab filing
Like Aduhelm (aducanumab) lecanemab – also known as BAN2401 – is another amyloid-directed antibody but has a slightly different mechanism, targeting soluble amyloid beta protofibrils which ...
Hosted on MSN1y
New Treatments for Alzheimer’s Disease
The drugs, aducanumab (Aduhelm) and lecanemab (Leqembi), were approved in June 2021 and January 2023, respectively. Both drugs were developed by pharmaceutical companies Biogen and Eisai ...
Forbes1y
VA Will Cover Alzheimer’s Disease Drug Lecanemab, Provided A Detailed Set Of Inclusion And Exclusion Criteria Are Met
The VHA decision stands in contrast with Medicare’s National Coverage Determination (NCD) for amyloid-directed monoclonal antibodies, such as lecanemab and aducanumab. In April 2022, the Centers ...